Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC PLEB001 for steroid-refractory acute GVHD (GI involvement)
ChiCTR2300073965Phase 3Recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Jul 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amimestrocel in Acute Graft-Versus-Host Disease (aGvHD), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Overall response rate at Day 28. Started Jul 2023; status: recruiting.
02
Drugs
amimestrocel
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2300073965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073965.